Topic: hereditary angieoedema
After shepherding the injected HAE med Firazyr through approval, Jochen Knolle is working on an oral treatment for the disease.
BioCryst says its BCX7353 drug effectively treated acute hereditary angioedema attacks in a midstage trial, setting up a possible registration study.
Shire has posted positive results for its late-stage hereditary angioedema candidate SHP616 against a dummy treatment.
Shire's dominant position in the hereditary angioedema market just firmed up with stellar data for its new candidate lanadelumab.